Bionano Genomics, Inc. is a life sciences company that develops genomic analysis technologies designed to identify structural variation and other genetic abnormalities that may be difficult to detect with conventional sequencing methods. The company’s platform is used in research, clinical, and pharmaceutical applications, including studies of cancer, inherited disease, and genome biology.
Its primary product is the Saphyr system, an optical genome mapping platform that analyzes long, fluorescently labeled DNA molecules as they pass through nanochannel arrays. Bionano offers related consumables, labeling kits, and software, including tools for assembling and interpreting genome maps and detecting structural variants, copy-number changes, and other genomic alterations.
The company also provides data analysis, laboratory, and professional services intended to support genome mapping workflows. Its customers include academic and research institutions, hospitals and clinical laboratories, pharmaceutical and biotechnology companies, and government organizations in markets around the world.
Founded in 2003 and headquartered in San Diego, California, Bionano expanded its software and informatics capabilities through the acquisition of BioDiscovery in 2020. Erik Holmlin has served as the company’s chief executive officer and has been associated with its development of optical genome mapping as a commercial genomic technology.
AI Generated. May Contain Errors.
